A chronological record of peer-reviewed Selank research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Peptide research timelines are often misrepresented online. Claims about "how quickly Selankworks" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.
Primary mechanism studied: Tuftsin Analog / Immune-Neuro Modulation. Primary indications investigated: Anxiety reduction, Cognitive enhancement, Immune modulation.
Sleep polysomnography study examining selank effects on sleep architecture, sleep efficiency, and insomnia symptoms.
Pharmacogenetic study correlating BDNF Val66Met and DAT1 polymorphisms with individual selank response in anxiety patients.
Gene expression study examining selank effects on mRNA levels for BDNF, NGF, and neurotrophic signaling in primary neurons.
RCT in patients with social anxiety disorder assessing selank effects on fear of social evaluation and social cognitive performance.
Study measuring selank effects on serum IL-6, TNF-alpha, CRP, and other inflammatory markers in patients with anxiety.
Electrophysiologic study examining selank effects on GABA-A receptor coupling, chloride current, and GABAergic neuron activity.
Double-blind RCT of intranasal selank (0.3mg/dose) versus placebo in adults with generalized anxiety disorder measuring HAMA scores.
Microdialysis study measuring selank effects on prefrontal cortex dopamine and serotonin levels in anxious rodents.
Study measuring selank effects on MDA, hydrogen peroxide levels, and antioxidant enzyme (SOD, catalase, GPx) activities in stressed brain.
Pharmacokinetic and neuroimaging study demonstrating selank intranasal absorption, CNS penetration, and regional brain distribution.
Cognitive testing study examining selank effects on attention, working memory, and executive function in anxiety-disorder patients.
Study in stressed rats examining selank effects on T-cell proliferation, IL-2 production, and immune cell subset distribution.
Comparative study of selank versus tuftsin mechanisms, examining receptor binding, intracellular signaling, and gene expression effects.
Behavioral pharmacology study of selank anxiolytic effects using elevated plus maze, open field, and novelty-induced suppression of feeding.
Open-label extension of selank RCT assessing sustained efficacy, tolerability, and lack of dependence during 12-week continuous use.
RCT examining selank effects on both anxiety symptoms and cognitive parameters (attention, memory, processing speed) in anxious patients.
Animal study demonstrating selank produced anxiolytic effects comparable to benzodiazepines without sedation or dependence.
The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for Selank is L3 (Emerging Clinical Evidence): pilot human studies or limited clinical trials available. Treat each study as one data point, not a conclusion.
PeptideMark indexes 54 studies on Selank: 8 human studies, 28 animal studies, 12 in-vitro, and 6 reviews. The current evidence level is L3 — emerging clinical evidence.
The earliest indexed peer-reviewed study on Selank in the PeptideMark library was published in 2002 (Bulletin of Experimental Biology and Medicine). Research activity has continued through 2012.
Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.
Published research activity on Selank has slowed in recent years based on indexed studies. Ongoing investigator-initiated trials may exist that are not yet indexed.
Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.